Kexing Biopharm announced that has initiated a Phase 3 trial of human Interferon α1b inhalation solution, which the company is developing for the treatment of children with pneumonia or bronchiolitis associated with respiratory syncytial virus. According to Kexing, a Phase 1 trial of the inhalation solution was completed in October 2023 and demonstrated low systemic exposure and high exposure in the lung.
According to the announcement, “. . . due to various challenges such as specific requirements for the physicochemical and pharmacological properties of inhaled aerosol drugs, the uncertainty of therapeutic effects by depositing atomized drug particles in airways and lungs, as well as strict approval procedures for pediatric medication, inhaled protein therapeutics for children have yet to be marketed in China. Human Interferon α1b Inhalation Solution, another significant breakthrough in the antiviral field achieved by Kexing Biopharm, is expected to fill this market void.”
Read the Kexing Biopharm press release.
